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A RETROSPECTIVE COHORT STUDY TO DETERMINE THE RISK 
DIFFERENCE IN SURVIVAL IN LOCOREGIONAL RECURRENCE AND 
DISTANT DISEASE OF BREAST CANCER IN PREMENOPAUSAL WOMEN 
TREATED WITH BREAST-CONSERVING THERAPY OR MASTECTOMY AT 
MASSACHUSETTS GENERAL HOSPITAL 
ANAS L. NAJJAR 
 
ABSTRACT 
Purpose: The purpose of this study was to determine if there is a risk difference in 
survival in the first event of locoregional recurrence and distant disease in women who 
underwent breast-conserving therapy (BCT) compared with women who underwent 
mastectomy.  Premenopausal women with early-stage breast cancer and positive lymph 
node/s make up this group. 
Methods: Retrospective cohort study was conducted to answer this study question by a 
chart review. 
Results: The results of the study demonstrated that women with breast cancer who 
underwent mastectomy had higher risk of distant disease compared with breast-
conserving therapy.  Also women aged under 35 had an independent association with 
distant disease.  In addition, the type of surgery did not have a significant result 
association with locoregional recurrence. 
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Conclusions: These results support the fact that the breast-conserving therapy group had 
a low rate of distant disease compared with the mastectomy group.  Also they endorse the 
necessity to conduct further descriptive studies to address the association between type of 
surgery and locoregional recurrence.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
	  	   viii 
TABLE OF CONTENTS 
 
TITLE……………………………………………………………………………………...i 
COPYRIGHT PAGE……………………………………………………………………...ii 
READER APPROVAL PAGE…………………………………………………………..iii 
DEDICATION ................................................................................................................... iv	  
ACKNOWLEDGMENTS ................................................................................................... v	  
ABSTRACT ....................................................................................................................... vi	  
TABLE OF CONTENTS ................................................................................................ viii	  
LIST OF TABLES .............................................................................................................. x 
LIST OF FIGURES .......................................................................................................... xii	  
LIST OF ABBREVIATIONS ......................................................................................... xiii	  
BACKGROUND ................................................................................................................. 1	  
METHODS ........................................................................................................................ 13	  
RESULTS .......................................................................................................................... 19	  
DISCUSSION .................................................................................................................... 31	  
APPENDIX ....................................................................................................................... 41 
LIST OF JOURNAL ABBREVIATIONS ........................................................................ 41 
REFERENCES .................................................................................................................. 44	  
	  	   ix 
CURRICULUM VITAE ................................................................................................... 51	  
 
  
	  	   x 
LIST OF TABLES 
 
 
Table Title Page 
1 General characteristics of premenopausal women 
undergoing breast-conserving therapy (BCT) or 
mastectomy in the period 1990 – 2004 
20 
2 Locoregional recurrence events after Follow-up and 
each type of surgery 
23 
3 Distant disease events after Follow-up and each type of 
surgery 
24 
4 Subset analysis for locoregional recurrences and distant 
diseases according to mastectomy with and without 
radiation and positive margin 
24 
5 5- and 10-year locoregional recurrence free survival 
after each type of surgery 
25 
6 5- and 10-year distant disease free survival after each 
type of surgery 
26 
7 Univariate analysis of locoregional recurrences in 
premenopausal women with early-stage breast cancer 
and positive nodes 
 
29 
	  	   xi 
 
8 Multivariate analysis of locoregional recurrences in 
premenopausal women with early-stage breast cancer 
and positive nodes 
29 
9 Univariate analysis of distant diseases in premenopausal 
women with early-stage breast cancer and positive 
nodes 
30 
10 Multivariate analysis of distant diseases in 
premenopausal women with early-stage breast cancer 
and positive nodes 
31 
 
 
  
	  	   xii 
LIST OF FIGURES 
 
 
 
Figure Title Page 
1 Locoregional-recurrence-free survival in premenopausal 
women with early-stage breast cancer and positive nodes, 
according to type of surgery 
26 
2 Distant-disease-free survival in premenopausal women 
with early-stage breast cancer and positive nodes, 
according to type of surgery 
 
27 
 
 
  
	  	   xiii 
LIST OF ABBREVIATIONS 
 
AC ....................................................................................... Adriamycin Cyclophosphamide 
AJCC ........................................................................ American Joint Committee on Cancer 
ALND .............................................................................. Axillary Lymph Node Dissection 
BCT ........................................................................................... Breast Conserving Therapy 
BRCA ............................................................................. Breast Cancer Susceptibility Gene 
CMF ......................................................... Cyclophosphamide-Methotrexate-5-Fluorouracil 
EBCTCG ............................................. Early Breast Cancer Trialists’ Collaborative Group 
EC ......................................................................................... Epirubicin Cyclophosphamide 
ER ............................................................................................................ Estrogen Receptor 
HER-2 ........................................................... Human Epidermal Growth Factor Receptor-2 
IRB ............................................................................................. Institutional Review Board 
JAMA .................................................... The Journal of the American Medical Association 
LVI ............................................................................................ Lympho-Vascular Invasion 
MGH ................................................................................... Massachusetts General Hospital 
NSABP ............................................ National Surgical Adjuvant Breast and Bowel Project 
PR ...................................................................................................... Progesterone Receptor 
RT ............................................................................................................ Radiation Therapy 
SLND ................................................................................ Sentinel Lymph Node Dissection 
TNM ............................................................................................... Tumor Node Metastases 
US .................................................................................................................... United States 
	  1 
BACKGROUND 
 
Purpose 
The purpose of this study was to determine if there is a risk difference in the first event of 
locoregional recurrence and distant disease in women who underwent breast-conserving 
therapy (BCT) compared with women who underwent mastectomy.  Premenopausal 
women with early-stage breast cancer and high-risk of locoregional recurrence and 
distant disease, i.e., positive lymph node/s only make up this group. 
Study Rationale  
Women with treated invasive breast cancer in all stages are at risk of experiencing 
locoregional recurrence (reappearance of cancer in the breast, overlying skin, underlying 
muscles or regional lymph nodes on the same side as the primary tumor was) and/or 
distant disease (spread of cancer from the primary tumor to organs or lymph nodes 
beyond the area of locoregional recurrence).1 
In a study of women with early-stage breast cancer, recurrence rates were 11% at five 
years of follow-up and 20% at 10 years after adjuvant therapy completion.2  Also others 
reported in regard to the local treatment, women with early-stage breast cancer had about 
10-15% risk of locoregional recurrence occurring after BCT and about 5-10% after 
mastectomy.3  However, most trials showed no difference in overall survival between the 
BCT and mastectomy.4 
Many trials addressed the fact that young age is associated independently with 
locoregional recurrence.5  It is also associated with a more aggressive disease.6  Young 
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women who underwent BCT were associated with a higher rate of  locoregional 
recurrence compared with women who underwent mastectomy.7  Locoregional recurrence 
demonstrated a possibility of high mortality.8  There was some disagreement how young 
was defined, but it was mostly up to 35 – 50 years.6  Besides genetic reasons, hormonal 
factors (e.g., estrogen and progesterone) are associated with breast cancer growth.9  This 
risk increases with late menopause because of the longer exposure to ovarian hormones, 
while premenopausal oophorectomy (removal of ovaries) decreases this risk.9 
This study provides information about locoregional recurrence in premenopausal early-
stage breast cancer women (this is the first generally acknowledged publication to 
address premenopausal women as a predictor) who have been selected as high-risk 
disease for locoregional recurrence and distant disease, i.e., positive lymph node/s only.  
This study includes factors such as lymphovascular invasion status, extracapsular 
extension, which have the potential to increase risk of locoregional recurrence in this 
group of women.  This risk could be a surrogate marker for tumor aggressiveness and 
tumor spreading to more distant sites especially in this age group.  So local treatment 
(type of surgery) might eliminate this risk, reduce further surgeries and improve overall 
survival. 
Breast Cancer  
Epidemiology 
Breast cancer is the most common cancer in women in the United States and the second 
most common cause of death from cancer in American women.10 
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In 2014, the American Cancer Society estimated 232,670 new cases of breast cancer in 
women, which represents about one-third of all new cancer cases among women in the 
U.S.11  There are also expected to be 40,000 deaths due to breast cancer in women in the 
U.S.11  Despite the fact that breast cancer in premenopausal women is uncommon, it is 
the most common cause of death in women aged 20-59 years.11  
Prognostic Factors 
Early-stage breast cancer women (stage I and II) may be exposed to circumstances of 
undertreatment (not receive enough or/and proper treatment) or overtreatment (received 
more than the required treatment).12  Identifying the prognostic factors for the tumor 
spreading in the patient could help in administering the proper treatment (medications or 
surgery) to minimize the possibility of recurrence.12  The prognostic factors include:  
1. Age 
Age is a strong prognostic factor for risk of locoregional recurrence and distant disease.13  
Many studies demonstrated that women who develop breast cancer at age 35-50 have a 
higher risk of locoregional recurrence compared with women diagnosed older than 50 
years of age.14  The reason behind that is still not fully understood.13 
2. Race 
Although there is no direct association between race and locoregional recurrence or 
distant disease, Hispanic and African American women are at high risk for breast cancer 
at a young age and the tumors tend to be aggressive with the potential spreading.15,16 
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3. Tumor Stage 
The most widely used method for breast cancer staging is the American Joint Committee 
on Cancer and the International Union for Cancer Control (AJCC-UICC) classification 
system for primary tumor size, lymph node involvement, and presence or absence of 
distant metastasis (TNM).17  There are two types of staging; clinical and pathological 
staging.18  The clinical staging (cTNM) is determined before the pathology results and 
after the physical examination and imaging.18  Wile the pathological staging (pTNM) is 
determined after the pathology results and surgery.18  While clinical staging does not 
usually give the exact tumor-staging status, the pathological staging does identify the 
accurate tumor staging and is used by most clinical trials.18 
a. Primary Tumor (T) 
See information about “T” stage in Appendix 1. 
In women with breast cancer, the risk of locoregional recurrence and distant disease were 
increased with large tumor size.5  After 10 years of follow-up, the locoregional recurrence 
rate was 15.9% in tumors ≤ 2 cm, and was 26.1% in tumors > 5 cm.5  In the same 
population, the risk of distant disease rate was 34.2% in tumors ≤ 2 cm, while the rate 
increased to 40.5% in tumors > 5 cm (and reached 66.4%) for T4 tumors.5 
b. Lymph Nodes (N) 
See information about “N” stage in Appendix 2. 
Presence or absence of positive lymph node/s on the same side as the primary tumor is a 
strong prognostic tool for locoregional recurrence and distant disease after treatment.19  
From N0 to N3, there was roughly a twofold increase in the actuarial rate of locoregional 
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recurrence.18  Similarly, the distant disease actuarial rate increased about three times from 
N0 to N3.18  
4. Histologic Types 
Most breast cancer develops from the epithelia of lobules or ducts.16  Breast cancer 
pathology is divided into two main types based on basement membrane involvement; 
noninvasive and invasive breast cancer.16 
Approximately 91% of the invasive breast cancers are either ductal or lobular types:20 
a. Invasive ductal carcinoma or infiltrating ductal carcinoma: 
This is the most common type of invasive breast cancer, dominating about 80% of 
all cases of invasive breast cancers.18  They tend to spread to the regional axillary 
lymph nodes.18   
b. Invasive lobular carcinoma or infiltrating lobular carcinoma: 
This is the second most common type of invasive breast cancer, accounting for 
about 10% of all invasive breast cancer.21  This type of cancer has a 16% lower 
risk of recurrence than invasive ductal carcinoma.22  It tends to spread to multiple 
sites, mainly to bone and liver.23 
5. Grade or Differentiation 
The most widely used system to determine the grade of the breast cancer is the Elston-
Ellis grading system.24  It is a modification of the Scarf-Bloom-Richardson system.24  
This method involves three features: degree of tubular formation (how much of the tumor 
tissue has normal breast ducts structures)25 and/or gland formation, nuclear pleomorphism 
(evaluation of the size and shape of the nucleus), and degree of mitotic activity (how fast 
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the cell divides).24  A score of 1-3 is assigned based on the presence/absence of each 
feature.24  A final score of 1 is a favorable score while 3 is the worst score.24 
o Grade 1 = Well differentiated. 
o Grade 2 = Moderately differentiated. 
o Grade 3 = Poorly differentiated. 
Tumor size is associated with tumor grades, i.e., the larger the tumor, the poorer the 
differentiation and vice versa.12   
In a study, tumor grade one was associated with 0% actuarial rate locoregional recurrence 
and it reached 21.3% in grade three.5 
6. Lymphovascular Invasion (LVI) 
Lymphovascular invasion occurs when tumor cells invade nearby lymphatic vessels or 
blood vessels.18  The presence of LVI is associated with poor prognosis, especially in 
poorly differentiated tumors.18,26  In a study, LVI was associated with risk of local 
recurrence and death.27 
7. Extracapsular Extension 
Extracapsular extension is a cancer extended beyond the lymph node wall.28  It is an 
indicator for an increased risk of locoregional recurrence.28 
8. Margin Status 
According to the National Surgical Adjuvant Breast and Bowel Project (NSABP), 
negative margin is the absence of invasive disease within at least 2 mm of the inked 
margin.12  Women with negative margins are associated with lower rates of local 
recurrence than those with positive margins.29 
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9. Receptors 
The most used molecules are steroid hormone receptors (estrogen ER and progesterone 
PR) and human epidermal growth factor receptors (HER family e.g. HER-2 or erb-
B2/neu).12   
a. Estrogen and Progesterone Receptors 
ER negative breast cancer patients are associated with more frequent locoregional 
recurrence and more aggressive tumors than are ER positive patients.12,18,30 
Fewer ER-positive cases are seen in premenopausal women than in postmenopausal 
women.18 
b. HER-2 Overexpression 
Testing for HER-2 receptor could help to determine the proper treatment.12   
Previous trials have demonstrated that women with HER-2 positive have a less favorable 
outcome than women with HER-2 negative.31  Treating HER-2 positive patients may 
reduce the risk of locoregional recurrence in comparison with untreated patients.32 
10. Genetic Factor 
Breast cancer susceptibility gene 1 and 2 (BRCA1/BRCA2) gene mutations are 
associated with increased risk of local recurrence by 12.9% after ten years.33  However, 
this effect generally only appears after an extended period of follow-up.33 
Management 
Management of the Primary Tumor 
In the mid 20th century, breast cancer was thought to spread by moving away from the 
breast cancer location to adjacent structures in a centrifugal fashion.12  Halsted’s radical 
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mastectomy in 1894 was the first treatment approach to breast cancer, based on the 
theory to ensure that there would not be any residual cancer.34  This local resection 
provided an effective way to prevent the tumor from spreading and subsequent death.34  
This surgery included removal of the breast, overlying skin, and underlying pectoralis 
muscles with removal of the regional lymph nodes (all axillary lymph nodes).12  In the 
1970s, as breast cancer patients continued to die, a new understanding developed about 
how breast cancer spread: so, in addition to centrifugal spread, there is spreading to more 
distal sites via the lymphovascular vessels.12  Since then, all recent managements have 
been based on both local and regional approaches, which include surgery, radiation and 
systemic treatment.12  
Soon after, Halsted’s aggressive procedure received less interest since there was no 
difference in survival outcomes in mastectomies and less aggressive surgeries.12  This has 
been confirmed in multiple clinical trials,  including the most respected trial; the NSABP 
B-04 (the National Surgical Adjuvant Breast and Bowel Project).35  This study 
demonstrated there was no differences in survival between radical mastectomy, and total 
mastectomy (removal of the breast only with no lymph node or muscles removal), and 
radiation with respect to women with negative or positive nodes.35 
The early stages of breast cancer (i.e. stage I, II and III) with no distant metastasis can be 
treated only by excising the tumor (lumpectomy) or by excising the whole breast that 
involves the tumor (mastectomy).31  Patients with more locally advanced disease (i.e. T3 
or T4) must be treated by removing the whole breast that involves the tumor 
(mastectomy).31 
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Type of Surgeries 
a. Breast-Conserving-Therapy (BCT) or Lumpectomy 
BCT is a surgical procedure to remove the breast cancer and a small portion of normal 
breast tissue around the cancer (safe margin).12  Cosmetically the BCT preserves the 
breast with no difference in survival outcomes compared with mastectomy in women 
with early-stage invasive breast cancer.18   
Tumor size is a very crucial factor to determine the applicability of BCT, because large 
sized-tumors contraindicate BCT.31  In NASBP B-06, patients with early-stage breast 
cancer (Stage I and II) whose tumors were ≤ 4 cm were studies because typically tumors 
larger in size would the need for mastectomy.36  Also tumor size with respect to the breast 
size is an important factor to consider because large tumors in small breasts could be a 
contraindication to BCT.  In this instance a combined decision by the surgeon and the 
patient is important.31  
Tumor location could influence the choice of BCT especially with involvement of the 
center of the breast, the nipple or the skin.18 Also if the tumor is at two separate sites, this 
could affect the choice of BCT because sometimes it is hard to remove them with a single 
excision.18  
Lymph node status should not be a contraindication for BCT since clinical trials showed 
similar outcomes for both BCT and mastectomy regardless of lymph node status.18 
b. Mastectomy 
Mastectomy is a complete removal of the breast that involves the tumor.31  Modified 
radical mastectomy (MRM) has replaced the aggressive Halsted radical mastectomy.31  It 
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involves removal of all the breast, overlying skin, nipple, areola, pectoralis fascia, with 
the nearby axillary lymph nodes.31  This surgery was the standard of care for early-stage 
breast cancer patients before BCT.31  This procedure spares patients from RT since all the 
breast has been removed.31  However, RT could be used in case of involvement of many 
lymph nodes.31  This procedure has poor aesthetic results compared with BCT.31 
The main reasons for mastectomy in early-stage breast cancer are: 
- The tumor is at two or more separate sites.18 
- A large tumor size with respect to breast size (however, some patients would receive 
radiation before surgery (neoadjuvant RT) to reduce tumor size, followed by BCT).31 
- Patient’s choice: Some patients decide to undergo a mastectomy to avoid subsequent 
radiation, further biopsies, and the chance of local recurrence.37 
- In case of abnormal results or defects in BRCA1 or BRCA2, mastectomy would 
reduce the possibility of breast cancer by about 90%.37 
- Pregnancy is another reason to have a mastectomy since pregnancy is 
contraindicative for radiation.18 
- In case of positive margins even after multiple shaving and re-excisions to the 
affected area.18 
Radiation therapy (RT) 
The main reason for RT is to make sure any remaining microscopic tumors following 
either BCT or mastectomy are destoyed.38 
Almost always all patients who undergo BCT must receive breast RT to ensure that any 
microscopic residual cancer is cured.39  Administration of RT is in the form of whole 
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breast RT.39  Seventeen previous clinical trials were conducted to compare RT following 
BCT vesus BCT alone.40  These studies involved 10,801 women with breast cancer with 
either positive nodes or negative nodes, and after ten years of follow-up, results showed 
that RT reduced recurrence (locoregional and distant) from 35% to 19.3%.40  RT also 
reduced subsequent death from breast cancer in one out of four recurrences.40  Significant 
results as well were found among women with only positive nodes.40   
Among women with mastectomy, RT can help to reduce chest wall recurrence and 
subsequent death.18  Most studies agreed that use of RT after mastectomy in patients with 
a tumor size ≥ 5 cm or more than three pathologically positive nodes is mandatory.18    
Systemic Therapy 
Systemic therapy involves treatment that affects the whole body, not restricted to the 
breast.31  Its objective is to make sure no cancer cells spread to more distant locations 
from the breast.31   
The Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) demonstrated from 
60 trials with over 28,000 women, that chemotherapy after surgery has a great impact on 
subsequent locoregional recurrences and death.31  This effect was seen mostly in women 
under 50 years of age.31  The most common regimen in practice involved Adriamycin and 
Cyclophosphamide (AC regimen), Epirubicin and Cyclophosphamide (EC regimen), or 
Cyclophosphamide-Methotrexate-5-Fluorouracil (CMF).31  In the 1990s, taxanes (e.g. 
paclitaxel and docetaxel) were introduced to the anthracyclin-based regimen.31 
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Hormonal Therapy 
Testing the presence or absence of ER or PR receptors in the breast cancer cells could 
help determine the proper treatment.12  Since hormonal therapy works against the 
estrogen receptor, women with ER-negative tumors do not receive this kind of 
treatment.31   The most common regimen is tamoxifen for five years.31 
Hormonal therapy after surgery has demonstrated a 25% reduction in locoregional 
recurrences and death in women with hormone receptor-positive tumors regardless of 
menopausal status.31   
Management of Regional Lymph Nodes 
Just as breast cancer surgery for the primary tumor has gone through many changes, so 
has axillary lymph node management.18  Axillary lymph node dissection (ALND) was the 
mainstay of axillary lymph node management, where the surgeon would excise all lymph 
nodes in the armpit.12  Sentinel lymph node dissection (SLND) spared some breast cancer 
patients from having excessive surgery with dissection of a limited number of lymph 
nodes.18  A recent study demonstrated locoregional recurrence survival after ALND and 
SLND were not different.41 
Study Questions 
Primary Study Question 
Is there a difference in risk association with locoregional recurrence in premenopausal 
women with early-stage breast cancer and positive axillary lymph nodes who underwent 
breast-conserving surgery (lumpectomy) versus those who underwent mastectomy 
between 1990 and 2004 at Massachusetts General Hospital?   
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Secondary Study Question: 
Is there a difference in risk association with distant-disease recurrence in premenopausal 
women with early-stage breast cancer and positive axillary lymph nodes who underwent 
breast-conserving surgery (lumpectomy) versus those who underwent mastectomy 
between 1990 and 2004 at Massachusetts General Hospital?   
 
METHODS  
 
Study Design: Retrospective cohort study 
Group1: Women who underwent breast-conserving therapy. 
Group2: Women who underwent mastectomy. 
Institutional Review Board (IRB) approval was obtained from the Partners Health Care 
IRB before conducting any research activities.   
Every woman who met the inclusion/exclusion criteria and was diagnosed at 
Massachusetts General Hospital (MGH) between January 1st, 1990 and December 31st, 
2004 was identified through the MGH cancer registry. 
Primary outcome: 
Locoregional recurrence.  Defined as the time from the day of the pathological diagnosis 
to the first local or regional nodal recurrence.  Patients with distant disease, contralateral 
metastases, death, or last follow-up were not considered as locoregional recurrences. 
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Secondary outcome: 
Distant disease.  Defined as the time from the day of the pathological diagnosis to the 
first relapse beyond locoregional recurrence and contralateral recurrence.  Patients with 
locoregional recurrence, contralateral metastases, death, or last follow-up were not 
considered as distant disease. 
Study subjects selection: 
Women with breast cancer were selected according to the inclusion criteria.  SQL Server 
Management Studio 2012 software was used for the data extraction.42 
The following information was collected from the MGH Cancer Registry: date of 
diagnosis, age at diagnosis, last follow-up date, surgery date, race, primary site, laterality, 
histology, grade, AJCC stage, pTNM stage, tumor size, number of positive nodes, 
number of nodes examined, type of surgery, radiology therapy status, chemotherapy 
status, hormonal therapy status.  Longitudinal medical records (medical records) were 
used to determine the following for all patients: premenopausal status, margin status, 
BRCA1/BRCA2 status, estrogen receptor status, progesterone receptor status, HER-2 
status, extracapsular status, LVI status, and date and type of recurrence.  All patients with 
missing information about premenopausal status and date and time of recurrence were 
excluded. 
The seventh edition of the American Joint Committee on Cancer pathological tumor size, 
nodal status, and metastases staging systems was used.17 
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Study population: 
Inclusion criteria 
- Premenopausal women at time of diagnosis including all menstruating women and 
women who were within one year of their last period. 
- New primary breast cancer. 
- Unilateral tumor. 
- At least five years of follow-up after day of pathological diagnosis. 
- Histologically confirmed stage (T1 or T2, N1, M0) invasive breast carcinoma, with 
tumor size equal to or less than 4 cm. 
- Metastases to ipsilateral axillary lymph node. 
- Positive lymph nodes between one and three. 
- Diagnosed between January 1st, 1990 and December 31st, 2004. 
- BCT or mastectomy procedures. 
Exclusion criteria 
- Received neoadjuvant chemotherapy or radiotherapy. 
- Bilateral treatment for unilateral breast cancer. 
- Patients with prior history of invasive or in situ breast or other cancers (except those 
women treated for cutaneous basal or squamous cell carcinoma). 
- Patients who received nodal radiotherapy. 
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Data filtration: 
The process to extract the data involved many steps: 
- Extraction of data for patients diagnosed between 01/1990-12/2004 with new 
primary tumors, no previous tumors, invasive breast cancer, unilateral, at least five 
years follow up, tumor size equal or less than 4 cm, received BCT or mastectomy 
surgery, and age less than 65. Based on the above criteria, data from 3276 women 
were included.  
- Exclusion of patients with negative lymph nodes (1641 women). 
- Exclusion of patients with positive lymph nodes equal to or more than four (934 
women). 
- Exclusion of patients with nodal radiation (204 women) 
- Exclusion of patients with radiation therapy or chemotherapy before surgery (27 
women). 
- Exclusion of postmenopausal women at time of diagnosis (139 women). 
Based on the above inclusion and exclusion criteria, data from 331 patients were 
analyzed for this study. 
Statistical data analysis: 
Data variables at time of diagnosis were compared in the two arms (BCT and 
mastectomy) using the Wilcoxon rank sum test for continuous variables and the Chi-
Square test for categorical data.  
For locoregional-recurrence-free survival and distant-disease-free survival:  the Kaplan-
Meier method and the Log-rank test were used to compare the two arms at 5- and 10-
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years of follow-up.  For each outcome analysis, a graph represented the model with 
survival curves and the survival percentages with 95% confidence intervals and p-values 
were provided. 
The Cox proportional hazard model was used to study the univariate and multivariate 
association between (locoregional recurrence and distant disease) and type of surgery 
with some potential confounders (age, tumor size, and margin status).  For each variable 
hazard ratio, the 95% confidence interval and p-value were provided. 
Statistical analyses were performed with the use of the SAS 9.3 software.43  Results were 
considered statistically significant for a p < 0.05. 
Statistical power computation: 
The strategy to find an assumption for the recurrence rate was to find a recent study with 
an adequate sample size, comparable risks (e.g. age, tumor size), same time period (years 
of data collection), and similar outcome to this study population. 
A Dutch study demonstrated local recurrence risk difference between BCT and 
mastectomy after ten years was 18.4% and 6% respectively.44  Unlike the current study, 
the Dutch study involved both women with negative and positive nodes, also it was 
limited by age (up to 40 years of age), not by menopausal status.  Using SAS software 
with these figures yields a necessary sample size per group = 110, according to power = 
80%. 
Confounders 
The strategy for selecting the confounders based on finding the variables that have an 
association with the predictor and the outcome according to clinical guidelines, not 
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according to statistical findings in this study.  Few confounders included for in the Cox 
model.  They are: 
Age:   
Despite the fact that the type of surgery does not differ in breast cancer women according 
to age, in general BCT is more favorable to young women for quality of life reason.45  
Women younger than 50 years of age with early-stage breast cancer are more likely to 
undergo BCT than mastectomy.46  
Women younger than 35 years of age with early-stage breast cancer had proven to be 
associated with tumor spreading.7 
Tumor size:  
Tumor size is one of the crucial factors to determine type of surgery and predict 
locoregional recurrence and distant disease.  For women with tumors up to 5 cm (i.e. up 
to T2): those with smaller tumors would be more likely to receive BCT, while larger 
tumors would receive mastectomy or chemotherapy before surgery.47  On the other hand, 
with larger tumors, locoregional recurrence and distant disease are increased.5 
Margin status:  
Women with negative margins (no cancer on the inked margins) after biopsy do not need 
any further surgery, so biopsy would be called BCT.  While, women with positive 
margins (cancer on the inked margins) or close margins (in between negative and positive 
margins) are more likely to receive further surgery (re-excision).48  These women may 
elect mastectomy instead of re-excision.48 
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Positive margins are associated with higher risk of local recurrence or distant disease than 
negative margins.29  
 
RESULTS 
 
Description of population: 
In this study, data from 331 women who met the inclusion criteria and were analyzed for 
this study: 222 (67.07%) women received breast-conserving therapy (BCT), while 109 
(32.93%) women underwent a mastectomy.  The median follow-up time from the day of 
diagnosis to the last day of follow-up was 108 months (9.0 years) (Table 1).  
More than 90% of the population was Caucasian.  There were similar percentages with 
respect to follow-up time, grade, tumor location, histology, receptors, extracapsular 
extension, LVI, and chemotherapy.  The proportion of tumors > 2 cm was higher in the 
mastectomy group than the BCT group.  In the mastectomy group 20.2% of the women 
had a tumor size greater than 2 cm, while only 9% of the BCT group had tumors > 2 cm.  
The proportion of positive lymph nodes at levels two and three was relatively higher in 
the mastectomy group than the BCT group (Table 1)  
Fourteen of the 222 BCT patients (6.3%) experienced locoregional recurrence (13 local 
recurrences and 1 regional recurrence).  Two of 109 mastectomy patients (1.8%) 
experienced locoregional recurrence, including one local recurrence and one regional 
recurrence. 
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Table 1. General characteristics of premenopausal women undergoing breast-
conserving therapy (BCT) or mastectomy in the period 1990 - 2004. 
Characteristics Sub-
characteristic 
BCT 
(n=222) 
Mastectomy 
(n=109) 
p-value 
Median age at 
Diagnosis y (range)  
 45  
(28-56) 
44  
(29-55) 
0.029 
Median Follow-up in 
months (range) 
 
 110 
(60.9-254.6) 
106 
(60.9-245.5) 
0.22 
Follow-up within at 
least 10-years, n (%) 
 94 (42.3%) 40 (36.7%) 0.33 
Race, n (%) White 212 
(95.5%) 
105 
(96.3%) 
0.67 
 Hispanic 5 
(2.3%) 
3 
(2.8%) 
 
 Asian 5 
(2.3%) 
1 
(0.9%) 
 
Median Tumor Size 
in mm 
 15 16 0.0044 
Laterality, n (%) Left 117 
(52.7%) 
50 
(45.9%) 
0.25 
 Right 105 
(47.3%) 
59 
(54.1%) 
 
Tumor Size, n (%) 1-10  
mm 
57  
(25.7%) 
23  
(21.2%) 
0.039 
 11-20  
mm 
145 
(65.3%) 
64 
(58.7%) 
 
 21-30  
mm 
16 
(7.2%) 
17 
(15.6%) 
 
 31-40  
mm 
4 
(1.8%) 
5 
(4.6%) 
 
Median number of 
nodes examined, n 
(range) 
 10  
(1-33) 
14  
(1-29) 
<0.0001 
Number of lymph 
nodes examined, n 
(%) 
1-5 86 
(38.7%) 
11 
(10.1%) 
<0.0001 
 6-10 53 
(23.9%) 
32 
(29.4%) 
 
 11-15 35 
(15.8%) 
30 
(27.5%) 
 
 16-20 13 12  
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(5.9%) (11.0%) 
 21-25 5 
(2.2%) 
2 
(1.8%) 
 
 26-30 1 
(0.5%) 
0 
(0.0%) 
 
 31+ 29 
(13.1%) 
22 
(20.2%) 
 
Positive Lymph 
Nodes, n (%) 
1 156 
(70.27%) 
68 
(62.4%) 
0.35 
 2 48 
(21.6%) 
30 
(27.5%) 
 
 3 18 
(8.1%) 
11 
(10.1%) 
 
Grade, n (%) 1 44 
(19.8%) 
15 
(13.8%) 
0.019 
 2 104 
(46.9%) 
69 
(63.3%) 
 
 3 74 
(33.3%) 
25 
(22.9%) 
 
Primary Site, n (%) Nipple 
(Areolar) 
1 
(0.45%) 
2 
(1.8%) 
0.015 
 Central 
portion of 
breast 
6 
(2.7%) 
2 
(1.8%) 
 
 Upper inner 
quadrant 
19 
(8.6%) 
7 
(6.4%) 
 
 Lower inner 
quadrant 
8 
(3.6%) 
6 
(5.5%) 
 
 Upper outer 
quadrant 
77 
(34.7%) 
25 
(22.9%) 
 
 Lower outer 
quadrant 
17 
(7.7%) 
1 
(0.9%) 
 
 Axillary tail  5 
(2.3%) 
1 
(0.9%) 
 
 Overlapping 33 
(14.9%) 
23 
(21.1%) 
 
 NOS 56 
(25.2%) 
42 
(38.5%) 
 
Histology, n (%) Invasive 
Ductal 
199 
(89.6%) 
94 
(86.2%) 
0.07 
 Invasive 
Lobular 
7 
(3.2%) 
2 
(1.8%) 
 
 Both 14 7  
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(6.3%) (6.4%) 
 Others 2 
(0.9%) 
6 
(5.5%) 
 
Margin, n (%) Positive 35 
(15.8%) 
0 
(0.0%) 
<0.0001 
 Close 46 
(20.7%) 
10 
(9.2%) 
 
 Negative 141 
(63.5%) 
99 
(90.8%) 
 
BRCA1/BRCA2, n 
(%) 
Yes 8 
(3.6%) 
5 
(4.6%) 
0.55 
 No 15 
6.8%) 
14 
(12.8%) 
 
 Unknown 199 
(89.6%) 
90 
(82.6%) 
 
Estrogen receptor, n 
(%) 
Yes 183 
(82.4%) 
77 
(70.6%) 
0.01 
 No 39 
(17.6%) 
32 
(29.4%) 
 
Progesterone 
receptor, n (%) 
Yes 175 
(78.8%) 
74 
(67.9%) 
0.03 
 No 47 
(21.2%) 
35 
(32.1%) 
 
HER-2 receptor, n 
(%) 
Yes 45 
(20.3%) 
22 
(20.2%) 
0.97 
 No 170 
(76.6%) 
84 
(77.1%) 
 
 Unknown 7 
(3.2%) 
3 
(2.8%) 
 
Extracapsular, n (%) Yes 25 
(11.3%) 
11 
(10.1%) 
0.92 
 No 164 
(73.9%) 
75 
(68.8%) 
 
 Unknown 33 
(14.9%) 
23  
(21.1%) 
 
LVI, n (%) Yes 62 
(27.9%) 
24 
(22.0% 
0.58 
 No 128 
(57.7%) 
58 
(53.2% 
 
 Unknown 32 
(14.4%) 
27 
(24.8%) 
 
Radiotherapy, n (%) Yes 222 
(100.0%) 
39 
(35.8%) 
<0.0001 
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 No 0 
(0.0%) 
70 
(64.2%) 
 
Chemotherapy, n (%) Yes 220 
(99.1%) 
108 
(99.1%) 
0.99 
 No 2 
(0.9%) 
1 
(0.9%) 
 
Hormone therapy, n 
(%) 
Yes 184 
(82.9%) 
79 
(72.5%) 
0.027 
 No 38 
(17.1%) 
30 
(27.5%) 
 
 
Of the 331 patients, only 16 developed locoregional recurrence (BCT, n = 14 vs. 
mastectomy, n = 2), and 65 developed distant disease in the whole population (BCT vs. 
mastectomy, 37 vs. 28) (Tables 2 & 3).   
All locoregional recurrences in the mastectomy group occurred in the first five years of 
follow-up.  Approximately 90% of locoregional recurrences in the BCT group occurred 
in the first ten years of follow-up (Table 2).  
 
Table 2. Locoregional recurrence events after Follow-up and each type of surgery. 
Surgery type ≤ 5 years  5 – 10 years > 10 years All times 
BCT, n (%) 6 (42.9%) 6 (42.9%) 2 (14.2%) 14 (100%) 
Mastectomy, n 
(%) 
2 (100%) 0 0 2 (100%) 
 
For the distant disease, approximately 50% of all events occurred in the first five years of 
follow up in both groups.  Thereafter, the reported cases in both groups were 
approximately 30% and 15% at 5-10 years and at > 10 years, respectively (Table 3).  
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Table 3. Distant disease events after Follow-up and each type of surgery. 
Surgery type ≤ 5 years  5 – 10 years > 10 years All times 
BCT, n (%) 22 (59.5%) 11 (29.7%) 4 (10.8%) 37 (100%) 
Mastectomy, n 
(%) 
13 (46.2%) 9 (32.1%) 6 (21.4%) 28 (100%) 
 
Locoregional recurrence occurred in women who underwent mastectomy with no RT in 
two cases (2.9%) while no locoregional recurrence occurred in women who underwent 
mastectomy with RT.  Also distant disease occurred in women who underwent 
mastectomy with no RT in 18 cases (25.7%) while ten women (25.6%) occurred in 
mastectomy with RT experienced distant disease (Table 4).   
 
Table 4. Subset analysis for locoregional recurrences and distant diseases according 
to mastectomy with and without radiation and positive margin. 
Characteristics Locoregional 
recurrence 
Distant disease p-value 
Mastectomy without  
RT, n (%) 2 (2.9%) 18 (25.7%) 0.0001 
Mastectomy With RT, n 
(%) 0 10 (25.6%) 0.0007 
Positive margins, n (%) 0 5 (14.3%) 0.0203 
 
In the BCT group, there was about a 4% reduction in the locoregional-recurrence-free 
survival between the 5- and 10-year follow-up.  While the mastectomy group showed no 
difference between the 5- and 10- year locoregional-recurrence-free survival (Table 5). 
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Table 5. 5- and 10-year locoregional-recurrence-free survival after each type of 
surgery. 
Follow-up BCT group Mastectomy group 
5-year Locoregional-
recurrence-free survival, 
% (95% CI) 
97.30% (94.1%-98.8%) 98.17% (92.86%-99.54%) 
10-year Locoregional-
recurrence-free survival, 
% (95% CI) 
93.27% (87.68%-96.37%) 98.17% (92.86%-99.55%) 
 
In Figure 1, the survival proportions for the locoregional recurrence in both groups were 
very similar to each other in the first 10 years.  After that there was a trend toward 
reduction in the BCT survival compared with the mastectomy group. 
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Figure 1: Locoregional-recurrence-free survival in premenopausal women with 
early-stage breast cancer and positive nodes, according to type of surgery.  BCT 
breast conserving therapy, Mast mastectomy. 
 
There were approximately 7% and 13% reduction in the distant-disease-free survival 
after 5- and 10-year in the BCT and the mastectomy groups, respectively (Table 6). 
 
Table 6. 5- and 10-year distant-disease-free survival after each type of surgery. 
Follow-up BCT Mastectomy 
5-year distant-disease-
free survival, % (95% 
CI) 
90.09% (85.34%-93.36%) 88.07% (80.35%-92.89%) 
10-year distant-disease-
free survival, % (95% 
CI) 
82.98% (76.65%-87.73%) 74.41% (62.27%-83.51%) 
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In Figure 2, The BCT group survival was higher than the mastectomy group at all time 
points.  The difference between survivals for the two groups was prominent after 10 years 
of follow-up.  
 
 
 
 
 
 
 
 
Figure 2: Distant-disease-free survival in premenopausal women with early-stage 
breast cancer and positive nodes, according to type of surgery.  BCT breast 
conserving therapy, Mast Mastectom
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Analysis of locoregional recurrence  
The risk of locoregional recurrence in the BCT group increased by about three times 
compared with the mastectomy group (Table 7).  However, this risk did not change after 
controlling for the confounders (Table 8).  However, these results were not statistically 
significant in the univariate and the multivariate analysis. 
For women < 35 years of age, the risk of locoregional recurrence was approximately two 
times of those with age ≥ 35.  This risk did not change after controlling for the 
confounders.  However, this risk was not statistically significant in the univariate and the 
multivariate analysis (Tables 7 & 8). 
Risk of locoregional recurrence in women who had tumors ≤	 2 cm was not different 
compared with women who had tumors > 2 cm.  This risk did not change after 
controlling for the confounders.  These results were not statistically significant in the 
univariate and the multivariate analysis (Tables 7 & 8). 
During the construction of the univariate and the multivariate models, margin status 
dropped off as a confounder because there was not any woman with locoregional 
recurrence had positive margin, so margin status could not be included in the models 
(Tables 7 & 8). 
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Table 7. Univariate analysis of locoregional recurrences in premenopausal women 
with early-stage breast cancer and positive nodes. 
Characteristics Hazard Ratio (95% 
confidence interval) 
p-value 
Surgery type   
Mastectomy 1 (Reference)  
Breast Conservation Therapy 3.28(0.745-14.43) 0.12 
Age   
<35 1 (Reference)  
>=35 0.45 (0.10 - 1.99) 0.29 
Tumor size   
<=20mm 1 (Reference)  
>20mm 1.06(0.24-4.65) 0.94 
 
Table 8. Multivariate analysis of locoregional recurrences in premenopausal women 
with early-stage breast cancer and positive nodes. 
Characteristics Hazard Ratio (95% 
confidence interval) 
p-value 
Surgery type   
Mastectomy 1 (Reference)  
Breast Conservation Therapy 3.41(0.77-15.16) 0.11 
Age   
<35 1 (Reference)  
>=35 0.43(0.098-1.92) 0.27 
Tumor size   
<=20mm 1 (Reference)  
>20mm 1.20(0.27- 5.37) 0.81 
 
Analysis of distant disease 
There was about 40% less risk of distant disease in patients who received BCT compared 
with the mastectomy group.  In other words, for all women who had distant disease, there 
were six women who had BCT for every ten women who had mastectomy (Table 9).  
This risk was almost the same with controlling for the confounders (Table 10).  This 
result was statistically significant in the univariate and the multivariate models. 
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There was an approximate 60% increased risk of distant disease in women < 35 years of 
age compared with women ≥ 35 years.  Here, too, the risk was also to be seen after 
controlling the confounders with statistically significant results (Table 9 & 10). 
Risk of distant disease in women who had tumors ≤ to 2 cm was not different compared 
with women who had tumors > 2 cm.  This risk did not change much after controlling the 
confounders.  These results were not statistically significant in the univariate and the 
multivariate analysis (Tables 9 & 10). 
Women who had positive margins were not different in risk of distant disease compared 
with women who had negative margins; this risk did not change much after controlling 
the confounders.  The results in the univariate and the multivariate analysis were not 
statistically significant (Tables 9 & 10). 
Table 9. Univariate analysis of distant diseases in premenopausal women with early-
stage breast cancer and positive nodes. 
Characteristics Hazard Ratio (95% confidence 
interval) 
p-value 
Surgery type   
Mastectomy 1 (Reference)  
Breast Conservation 
Therapy 
0.59(0.36-0.96) 0.03 
Age   
<35 1 (Reference)  
>=35 0.41 (0.19 – 0.86) 0.02 
Tumor size   
<=20mm 1 (Reference)  
>20mm 1.05(0.50-2.21)          0.89 0.89 
 
Margin   
Negative 1 (Reference)  
Close 1.30(0.71-2.36) 0.40 
Positive 0.79(0.31-1.98) 0.61 
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Table 10. Multivariate analysis of distant diseases in premenopausal women with 
early-stage breast cancer and positive nodes. 
Characteristics Hazard Ratio (95% confidence 
interval) 
p-value 
Surgery type   
Mastectomy 1 (Reference)  
Breast Conservation 
Therapy 
0.57(0.33-0.97) 0.036 
Age   
<35 1 (Reference)  
>=35 0.44(0.21-0.93) 0.031 
Tumor size   
<=20mm 1 (Reference)  
>20mm 0.89(0.42-1.88) 0.75 
Margin   
Negative 1 (Reference)  
Close 1.45(0.78-2.69) 0.24 
Positive 0.99(0.38-2.61) 0.99 
 
DISCUSSION 
 
This study investigated 331 premenopausal women diagnosed with early-stage breast 
cancer and positive nodes at Massachusetts General Hospital Cancer Registry and 
analyzed for the purposes of demonstrating which surgery type (BCT vs. mastectomy) is 
associated with a higher risk of locoregional recurrence and distant disease. With this 
study, the type of surgery may disrupt the chain order of tumor spreading (local primary 
tumor, local recurrence, distant metastasis, and subsequent death).  Data for these patients 
were available for a median follow-up period amounting to nine years.  The study found a 
significant advantage of BCT over mastectomy with respect to the occurrence of distant 
disease.  Conversely, this study was not able to provide a statistical advantage difference 
between groups with respect to risk of locoregional recurrence.  However, this risk was 
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fairly high in the BCT group compared with the mastectomy group.  The locoregional 
recurrence risk difference in this study could be solely a matter of chance or may be due 
to a low incidence of locoregional recurrences in this particular population. 
The two cohorts examined were similar with respect to follow-up time, grade, tumor 
location, histology, receptors, extracapsular extension, LVI, and chemotherapy (Table 1).  
These factors were documented in the literature as risks for locoregional recurrence and 
distant disease (background section).  However, there were similar proportions of these 
factors in the study groups, so these factors were not expected to play a role in disturbing 
the association between type of surgery and locoregional recurrence or distant disease. 
Approximate 90% of all locoregional recurrences occurred in the BCT group.  The 5-year 
and 10-year locoregional-recurrence-free survival rates were over 90% in both study 
groups (Table 5).  The high survival rate for this group of women was likely due to the 
many different therapeutic modalities (different adjuvant therapies) they received.  Also 
there was only a 4% reduction in the BCT locoregional-recurrence-free survival rate from 
the 5-year to the 10-year follow-up.  There was no change in this survival rate for women 
who underwent mastectomy between five and ten years.  These survival rates were very 
similar to the women who received adjuvant therapies in the study used for the power 
calculation, where it found local-recurrence free survival for the BCT group at 5-years 
approximately around 95% and at 10-years around 90%.44  While local-recurrence free 
survival for the mastectomy group was unchanged from 5-years and 10-years 
approximately above 95%.44  This observation supports the major role of the adjuvant 
therapies to the addition of surgery against tumor recurrences. 
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Figure 1 showed no differences in survival between the two groups in the first five years.  
However, after that, there were more locoregional recurrences in the BCT group 
compared with the mastectomy group.  This can be accounted for by more breast tissue 
being left uncut after BCT surgery than after mastectomy.  Reappearance of Breast 
cancer is most commonly manifested as recurrence in the same area around the original 
cancer occurrence (local recurrence).12  The more breast tissue around the primary tumor 
(as in BCT), the higher the chance toward local recurrence, with a higher risk of 
subsequent mortality than those without local recurrence. 
It has previously been observed that locoregional recurrence usually occurs more later 
after BCT than after mastectomy.49  This concurs with our findings.  Approximately 50% 
of the recurrences in the BCT group occurred within five years, while 100% of 
recurrences in the mastectomy group occurred in the first five years (Table 2).  In another 
study, it was explained that late recurrences that occurred after BCT were mostly new 
primary tumors, while those occurring after mastectomy were mostly true recurrences, 
and so would manifest earlier.4  True recurrences and new primary tumors may have 
different prognoses.50   The current study did not differentiate between true recurrence 
and new primary tumor unfortunately.   
Researchers reported that women with positive margins are associated with a higher risk 
of locoregional recurrence.29  A majority of the total population had negative margins.  
But all positive margins occurred in the BCT group (Table 4), which was expected 
because BCT surgery is linked with positive margins.51  Missing information on 
subsequent shaving surgeries or re-excisions might partly explain the elevated number of 
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locoregional recurrences in the BCT group.  It was surprising to find none of the women 
with positive margins had locoregional recurrence, unlike researcher reported.  So an 
influence on the association between type of surgery and locoregional recurrence is 
unlikely. 
It is noticeable that approximately 40% of axillary dissections in the BCT group were 
restricted to just one to five lymph nodes (Table 1). Leaving other axillary lymph nodes 
uncut would expose them to risk of subsequent regional recurrence.  However, the entire 
BCT group experienced only one regional recurrence (same side axillary lymph node).  
This finding could be compared to the Z11 trial that revolutionized the necessity to do 
ALND.41 So with less aggressive surgery in the regional lymph nodes would spare 
patients from developing subsequent side effects e.g. pain, infections, lymphedema (arm 
swelling). 41 
The data regarding locoregional recurrence in this study supports results of pooled (from 
two large randomized studies) analyses from Voogd et al.  Voogd et al. showed that there 
was a 28% higher absolute increase of the local recurrence rate in the BCT group over 
mastectomy after 10-year follow-up.4   In contrast, the NASBP-06 study, the largest 
randomized trial that compared two treatment arms with respect to locoregional 
recurrence, found that BCT had a significant advantage over mastectomy.6,36  However, in 
the NASBP-06 study only 40% of the women were younger than 50 years of age with no 
subset analysis regarding the age.6  It also included both negative and positive axillary 
lymph nodes.6  Lastly, the local recurrence in the same breast as the primary tumor that 
occurred after BCT surgery was considered a cosmetic failure, unlike the current study’s 
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definition of local recurrence.6  These factors may contribute to the inconsistency in 
results with this study. 
This study showed fewer locoregional recurrences than the study of the power 
calculation.  This is may be attributed to the factor of age.  Age of the women in the 
Dutch study was up to 40 years, while the current study’s median age was 45 years.44  
Women with age < 50 years are at higher risk of locoregional recurrence than > 50 
years.14  So may be young age has a higher risk for locoregional recurrence than 
premenopausal status. 
In Table 6, the BCT group demonstrated a statistically significant advantage in distant-
disease free survival after 5- and 10-years of follow-up versus the mastectomy group.  
The survival rates decreased in the mastectomy group about twice as much as in the BCT 
group.  This finding was similar to that of another study, where younger patients with 
stage II disease exhibited 10-year actuarial distant disease rates of 19.5% for BCT, and 
33.9% for mastectomy, p=0.006.5  Death rate of women with distant disease is four-times 
bad as in women with tumors confined to the breast.52 
This study identified that women younger than 35 years of age was an independent 
predictor for risk of distant disease.  This result was statistically significant and 
concurrent with findings elswhere.7  This study’s finding was independent of surgery 
type, margin or tumor size.  This finding could be due to an increase incidence of distant 
disease in young age in the last 40 years as the recent JAMA publication reported, with 
no clear reason behind that.53 
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Figure 2 showed that distant disease-free survival differences between groups became 
evident after ten years of follow-up in favor of the BCT group.  This may be explained by 
the fact that a greater percentage of women in the BCT group received hormonal therapy 
in the BCT group compared with the mastectomy group (83% vs. 73%, respectively).  A 
study demonstrated that tamoxifen for 5 years had a carry-over effect in reduction of 
subsequent recurrences up to 15 years.54  According to this finding, all women with the 
same study criteria should be advised about the 5-years regimen hormonal therapy. 
The finding of this current study may be explained by breast cancer milestones: 
inception, diagnosis and distant disease.55  In this study, it could be most of the patients 
who had distant metastasis were diagnosed late, i.e. the period from breast cancer 
inception to day of diagnosis was long, while those women without distant disease may 
have been diagnosed earlier, i.e. the period from breast cancer inception to day of 
diagnosis was short.  So whoever received a late diagnosis after tumor inception may 
have an increased risk for the tumor spreading to distant sites.  This could apply to the 
current study since tumors > 2cm in size were more frequent and a slightly higher 
proportion of patients had either two or three positive lymph nodes in the mastectomy 
group than in the group undergoing BCT.   Premenopausal women should be advised 
about the necessity to undergo the required screenings that might detect the disease early 
and in turn reduce risk of distant disease.  
Radiation therapy always plays a major role in reducing subsequent tumor spreading.  In 
this study, all women in the BCT group had undergone radiation therapy.  On the other 
hand, in the mastectomy group, only about one-third of the women had received RT.  
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Regarding locoregional recurrence, although all recurrences in the mastectomy group 
occurred in the non-RT women, there were very low percentages of locoregional 
recurrence in the BCT group and the mastectomy group (with or without RT) (BCT, 
6.3% vs. mastectomy with RT, 0% vs. mastectomy without RT, 2.9%) (Table 4).  
Regarding distant disease, although RT did not improve the proportion of distant disease 
in the mastectomy group as compared with the BCT group, there was a slight 
improvement in the BCT group over the mastectomy group with or without RT (16.7% 
vs. 25.6% vs. 25.7%, respectively).  This difference may be due to higher proportion of 
patients with tumors > 2cm and the slightly higher frequency of two or three positive 
lymph nodes in the mastectomy group compared with the BCT group.  These 
observations suggest that women in this study who chose mastectomy, RT had no 
importance in terms of distant disease.  So RT may not be necessary for women who 
chose mastectomy.  Also with low percentage of locoregional recurrences, judgment 
about the association between RT and locoregional recurrence in the mastectomy group 
cannot be made. 
Another aspect in this study is that BRCA test information was included for a limited 
number of patients.  Given the modest proportion (13%) of the study population tested 
and with more BRCA positive in the BCT arm than mastectomy, it could be unlikely that 
BRCA results biased surgery choice significantly.  In general, women with BRCA 
mutations are advised to undergo mastectomy to avoid the association with high 
subsequent tumor recurrence.33 
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Strengths 
This study has many potential strengths.  It is the first acknowledged study to include 
only premenopausal women instead of relying on certain age limits as other studies did.  
That might help to expand the knowledge about the potential favorable effect of each 
type of surgery to reduce risk of locoregional recurrence and distant disease in this group 
of women. 
The MGH tumor registry was used meticulously to collect data with an access to 
longitudinal medical records that acted as a reliable source of outcome data, some 
confounders and premenopausal status. Physician and other clinical staff used 
longitudinal medical records; it is a replacement for the paper medical record.   
Also this study included a wide range of prognostic factors (e.g. LVI, extracapsular 
extension and tumor receptors), helping to minimize any influence that these factors 
could play on the association of interest. 
The majority of the patients in this cohort received adjuvant therapy, which is a mainstay 
of modern treatment.  Adjuvant therapy plays a major role in prevention subsequent 
tumor recurrence. 
The median follow-up time was nine years, which was adequate to observe any of the 
outcomes of interest.  
Limitations  
This study also incurred several limitations.  The results of this study only can be 
generalized to the population at Massachusetts General Hospital.  So studying another 
population with similar characteristics is needed to confirm this study’s conclusion.  
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This study was a retrospective cohort study.  All retrospective studies are at risk of 
collecting missing data.  However, missing data were reasonably low in this study.  Also, 
it is difficult to ask this study question in a randomized trial.   
The study failed to identify any statistically significant independent predictor of 
locoregional recurrence risk.  However, it is unlikely to affect this study results since 
BCT surgery had a fairly large risk for locoregional recurrence compared with 
mastectomy surgery.  Lack of statistical advantage may be due to the low number of 
locoregional recurrences in this population of interest.   
Nor did this study make any distinction between true recurrence and second primary 
tumor.  They may have a different natural history.56  However, it is unlikely to affect this 
study results since the purpose of this study was to find the relative advantages or 
disadvantages of BCT and mastectomy as local control.   
Almost all women in this study were Caucasians.  The study did not include any African 
Americans.  It is considered unlikely that this would have influenced the real association 
of interest in this study because other studies have found that the association between the 
African Americans and local recurrences are mostly mediated through delay and 
irregularity in treatment.57  
Future Studies 
Since this study is limited by a low incidence of locoregional recurrence events, further 
study with more patients who have the same criteria as this study will be needed to expect 
more locoregional recurrences, and then we can report a more confident statement. 
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Because of limited information about the association between locoregional recurrence 
and overall survival (death rate) in particular with this group of women in particular, such 
further study would enrich the literature.   
It would also interesting to study the possible interaction between type of surgery and 
number of positive lymph nodes in regard to locoregional recurrence and distant disease.  
We would expect a stronger association between (type of surgery and number of positive 
lymph nodes) as the predictor and locoregional recurrence or distant disease as the 
outcome. 
A recent study demonstrated five different tumor subtypes according to genes, each has a 
different potential for tumor spreading.58  A study Incorporating such information into 
this study would enable researchers to understand precisely which surgery type was the 
best to reduce the potential recurrences in each of the five tumor subtypes, rather than 
relying on other factors, e.g. tumor size, nodal involvement or receptors.  
Conclusion 
This study found that women who underwent a mastectomy had a higher risk of distant 
disease.  It also identified women younger than 35 years of age as associated with distant 
disease.  The study showed that breast-conserving therapy had a fairly large risk of 
locoregional recurrence.  However, this risk lacked the statistical advantage, so further 
research is needed to address locoregional recurrence risk in this population of interest. 
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APPENDIX 
 
Appendix 1.  Table of primary tumor (T) stage for breast cancer 
TX Primary tumor cannot be assessed. 
T0 No evidence of primary tumor. 
Tis Carcinoma in situ. 
Tis (DCIS) DCIS. 
Tis (LCIS) LCIS. 
Tis (Paget) Paget disease of the nipple NOT associated with invasive carcinoma 
and/or carcinoma in situ (DCIS and/or LCIS) in the underlying 
breast parenchyma. Carcinomas in the breast parenchyma associated 
with Paget disease are categorized based on the size and 
characteristics of the parenchymal disease, although the presence of 
Paget disease should still be noted. 
T1 Tumor ≤20 mm in greatest dimension. 
T1mi Tumor ≤1 mm in greatest dimension. 
T1a Tumor >1 mm but ≤5 mm in greatest dimension. 
T1b Tumor >5 mm but ≤10 mm in greatest dimension. 
T1c Tumor >10 mm but ≤20 mm in greatest dimension. 
T2 Tumor >20 mm but ≤50 mm in greatest dimension. 
T3 Tumor >50 mm in greatest dimension. 
T4 Tumor of any size with direct extension to the chest wall and/or to 
the skin (ulceration or skin nodules). 
T4a Extension to the chest wall, not including only pectoralis muscle 
adherence/invasion. 
T4b Ulceration and/or ipsilateral satellite nodules and/or edema 
(including peau d'orange) of the skin, which do not meet the criteria 
for inflammatory carcinoma. 
T4c Both T4a and T4b. 
T4d Inflammatory carcinoma. 
Edge SB. AJCC Cancer Staging Handbook, From the AJCC Cancer Staging 
Manual. Springer Verlag; 2010. 
 
Appendix 2.  Table of Regional Lymph Nodes (N) 
 
NX Regional lymph nodes cannot be assessed (e.g., previously removed). 
N0 No regional lymph node metastases. 
N1 Metastases to movable ipsilateral level I, II axillary lymph node(s). 
N2 Metastases in ipsilateral level I, II axillary lymph nodes that are clinically 
fixed or matted. 
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OR 
Metastases in clinically detected ipsilateral internal mammary nodes in the 
absence of clinically evident axillary lymph node metastases. 
N2a Metastases in ipsilateral level I, II axillary lymph nodes fixed to one another 
(matted) or to other structures. 
N2b Metastases only in clinically detected ipsilateral internal mammary nodes 
and in the absence of clinically evident level I, II axillary lymph node 
metastases. 
N3 Metastases in ipsilateral infraclavicular (level III axillary) lymph node(s) 
with or without level I, II axillary lymph node involvement. 
OR 
Metastases in clinically detected ipsilateral internal mammary lymph 
node(s) with clinically evident level I, II axillary lymph node metastases. 
OR 
Metastases in ipsilateral supraclavicular lymph node(s) with or without 
axillary or internal mammary lymph node involvement. 
N3a Metastases in ipsilateral infraclavicular lymph node(s). 
N3b Metastases in ipsilateral internal mammary lymph node(s) and axillary 
lymph node(s). 
N3c Metastases in ipsilateral supraclavicular lymph node(s). 
Edge SB. AJCC Cancer Staging Handbook, From the AJCC Cancer Staging 
Manual. Springer Verlag; 2010. 
 
Appendix 3.  Table of AJCC stage with the corresponding TNM 
 
Stage  T  N  M  
0 Tis N0 M0 
IA T1 N0 M0 
IB T0 N1mi M0 
 T1 N1mi M0 
IIA T0 N1 M0 
 T1 N1 M0 
 T2 N0 M0 
IIB T2 N1 M0 
 T3 N0 M0 
IIIA T0 N2 M0 
 T1b N2 M0 
 T2 N2 M0 
 T3 N1 M0 
 T3 N2 M0 
IIIB T4 N0 M0 
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 T4 N1 M0 
 T4 N2 M0 
IIIC Any T N3 M0 
IV Any T Any N M1 
Edge SB. AJCC Cancer Staging Handbook, From the AJCC Cancer Staging 
Manual. Springer Verlag; 2010. 
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